Our Pipeline

Pipeline
Program Indication Preclinical Phase 1 Phase 2 Phase 3

GTX-104

aSAH

Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress

GTX-102

Ataxia-Telangiectasia

Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

GTX-101

Postherpetic Neuralgia

Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

GTX-201

Undisclosed

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

GTX-104

GTX-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for intravenous infusion (IV) in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTX-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion.

Learn More About GTX-104

GTX-102

GTX-102 is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population. AT is caused by mutations in the ataxia telangiectasia mutated (ATM) gene. Children with AT experience cerebellar ataxia and other motor dysfunctions, oculomotor apraxia, dysarthria, and dysphagia.

A Phase-1 pharmacokinetic study was successfully completed and GTX-102 is well tolerated with no serious events reported.

GTX-101

GTX-101 is a topical administration via a bioadhesive, film-forming polymer, for treatment of pain associated with postherpetic neuralgia (PHN).

Acasti has performed four single-dose Phase 1 studies to evaluate the PK, safety, dose proportionality and tolerability of GTX-101. No serious adverse events were reported and GTX-101 is well tolerated.

Partnerships

If you are interested in partnering with us, please contact us.

Contact Us for Partnership